글로벌 바이오인공장기 제조 시장 – 2030년까지의 산업 동향 및 예측

 생체인공장기제조시장 분석 및 규모

조직 손실이나 말기 장기 기능 부전이 있는 환자를 위한 의료 수술 치료는 전 세계 인구가 고령화되고 병리로 인해 장기 기능 진행이 제한되거나 영향을 받음에 따라 점점 더 일반화되고 있습니다. 미국 이식 재단에 따르면 장기 이식을 기다리는 사람은 약 114,000명이며, 장기 부족으로 인해 약 20명이 사망했습니다. 장기 이식에 대한 수요가 증가함에 따라 생체 인공 장기가 기증자 장기 부족을 완화하는 데 도움이 되면서 시장이 상당히 확대될 것으로 예상됩니다.

Data Bridge Market Research는 2022년에 231억 3천만 달러였던 생체인공장기 제조 시장이 2030년까지 420억 3천만 달러에 도달할 것으로 분석했으며, 2023년부터 2030년까지의 예측 기간 동안 연평균 성장률은 7.75%에 이를 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

생체인공장기제조시장 범위 및 세분화  

Market Definition

Bioartificial organ manufacturing technologies are a series of enabling techniques that can produce human organs based on bionic principles. Organ manufacturing technologies can be divided into three main groups: (1) fully automated, (2) semi-automated, and (3) handworked (or handmade). One of the most promising bioartificial organ manufacturing technologies is combining multi-nozzle three-dimensional printing techniques to assemble personal cells and other biomaterials to build exclusive organ substitutes for defective/failed human organs.

Global Bioartificial Organ Manufacturing Market Dynamics

Drivers

• Increased R&D activities

Factors such as increased product launches increased R&D activities, and key market players' strategies will drive the growth of the studied segment. Furthermore, the segment's growth is expected to be fuelled by new product approvals and ongoing government support. In February 2020, the U.S. Food and Drug Administration (FDA) granted Abbott Breakthrough Device designation for its in-development fully implantable left ventricular assist system. In March 2021, Penn State Health Milton S. Hershey Medical Center became the country's second hospital to implant a newly designed EvaHeart2 Left Ventricular Assist System (LVAS) in a patient with severe heart failure. These all are certain factors that propel the growth of the market.

• Increasing prevalence of organ failure

The rising prevalence of organ failure caused by severe infections, cardiovascular disease, and trauma increases the number of organ transplant surgeries. In 2019, the World Health Organization reported approximately 48.9 million cases of sepsis. Adopting bad habits like drinking and smoking leads to liver and heart failure. As the prevalence of such illnesses rises, so does the risk of organ failure, driving up demand for bioartificial organs.

Opportunities

• Advances in 3D bioprinting

Advances in 3D bioprinting have proven critical in organ transplantation because it is used to create artificial organs. 3D bioprinting is becoming increasingly popular because it reduces the risk of organ rejection. Furthermore, artificial intelligence is poised to alter global trends in artificial device usage. Many countries are currently focusing on a tool that provides a personalized assessment of organ and donor suitability. This tool will be extremely helpful in making informed decisions about organ retrieval and determining whether patients should accept donor organs or wait for better options.

Restraints/Challenges

• Side effects associated with artificial organs

Lack of skilled professionals, transplant side effects such as skin irritation, high procedure costs, low technology penetration in developing countries, and other factors are impeding the growth of the bioartificial organ market. The presence of the disease in the base tissue used to create the organ is a major concern. In such cases, the tissue may already be infected with another disease.

• High cost of artificial organs

The total cost of growing and transplanting an artificial organ is prohibitively expensive, limiting its application to the general public. There is a high risk of organ failure, and the body may require time to adjust to the new organ.

This bioartificial organ manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bioartificial organ manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Bioartificial Organ Manufacturing Market Scope

The bioartificial organ manufacturing market is segmented on the basis of degree of automation, materials, and process. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Degree of Automation

• Semi- Automated
• Fully Automated
• Handworked

 Materials

• Mechanical
• Biomechanical
• Biological

Process

• Architectural Predesign
• Preparation of Materials and Construction Tools
• Homogeneous/Heterogeneous Cell Assembling
• Post Multi-Tissue Maturation

Bioartificial Organ Manufacturing Market Regional Analysis/Insights

The bioartificial organ manufacturing market is analysed and market size insights and trends are provided by country, degree of automation, materials, and process as referenced above.

The countries covered in the bioartificial organ manufacturing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bioartificial organ manufacturing market because of the region's well-developed healthcare infrastructure and favourable reimbursement policies.

Asia-Pacific is expected to grow at the highest rate in the forecast period of 2023 to 2030 owing to the rising aging population, and lack of organ donors.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The bioartificial organ manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for bioartificial organ manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bio-artificial organ manufacturing market. The data is available for historic period 2011-2021.

Competitive Landscape and Bioartificial Organ Manufacturing Market Share Analysis

생체인공장기 제조 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 생체인공장기 제조 시장과 관련된 회사의 초점에만 관련이 있습니다.

생체인공장기 제조시장에서 활동하는 주요 기업은 다음과 같습니다.

• B. Braun SE(독일)
• 보스턴 사이언티픽 코퍼레이션(미국)
• 게팅게 AB. (스웨덴)
• 아비오메드(미국)
• 아사히카세이(일본)
• Berlin Heart (독일)
• CARMAT(프랑스)
• Jarvik Heart, Inc. (미국)
• 테루모 주식회사(일본)
• SynCardia Systems, LLC(미국)
• Nipro Europe Group 회사(일본)
• 메드트로닉(미국)
• Organovo Holdings Inc. (미국)
• 넥스이뮨(미국)
• Diabeloop SA(프랑스)
• 애드메시스(미국)
• 디파이메드(프랑스)
• Pancreum, Inc. (미국)
• 베타바이오닉스 주식회사(미국)
• 인테그라 라이프사이언스(미국) 

SKU-52351